Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose–escalation study

References

• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010 Jun;62(6):1576–1582.
   PubMed Web of Science ®Google Scholar
• Rudan I, Sidhu S, Papana A, et al. Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health. 2015;5(1):010409.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123.
   PubMed Web of Science ®Google Scholar
• FDA. Actemra® (tocilizumab) injection, for intravenous or subcutaneous use 2022 [cited 2022 10 August]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125276s134lbl.pdf
   Google Scholar
• EMA. RoActemra: EPAR - Product Information 2022 [cited 2022 10 August]. Available from: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf
   Google Scholar
• FDA. KEVZARA (sarilumab) injection, for subcutaneous use 2017 [cited 2022 10 August]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761037s001lbl.pdf
   Google Scholar
• Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017 Dec;76(12):2001–2008.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25 387(8):715–726.
   PubMedGoogle Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 Jun;16(6):335–345.
   PubMed Web of Science ®Google Scholar
• Yip RML, Yim CW. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. J Clin Rheumatol. 2021;27(8):e516–e524.
   PubMed Web of Science ®Google Scholar
• Dayer J-M, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15–24.
   PubMed Web of Science ®Google Scholar
• HHS. Common Terminology Criteria for Adverse Events (CTCAE) 2010 [cited 2022 2 August]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy.J Hepatol. 2016 [2016 Jun 01];64(6):1403–1415.
   PubMed Web of Science ®Google Scholar
• Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000 Oct;17(10):1278–1283.
   PubMed Web of Science ®Google Scholar
• Sheng Y, He Y, Huang X, et al. Systematic evaluation of dose proportionality studies in clinical pharmacokinetics. Curr Drug Metab. 2010 Jul;11(6):526–537.
   PubMed Web of Science ®Google Scholar
• Morcos PN, Zhang X, McIntyre C, et al. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther. 2013 Jul;51(7):537–548.
   PubMed Web of Science ®Google Scholar
• Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther. 2013 Jun;51(6):443–455.
   PubMed Web of Science ®Google Scholar
• Schwabe C, Illes A, Ullmann M, et al. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial. Expert Rev Clin Immunol. 2022 May;18(5):533–543.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang H, Wei H, et al. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men. Front Pharmacol. 2021;11:609522.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li X, Liu J, et al. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra ®) in Chinese healthy subjects. Ann Med. 2021 Dec;53(1):375–383.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015 Apr;74(4):694–702.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. [2012 Mar 31];379(9822):1214–1224.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019 Feb 7;133(6):511–520.
   PubMed Web of Science ®Google Scholar
• Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: a randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388–395.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017 [2017 Jul 01];13(7):399–409.
   PubMed Web of Science ®Google Scholar
• Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014;53(7):1321–1331.
   PubMed Web of Science ®Google Scholar
• Suwa T, Hogg JC, English D, et al. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2954–60.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Oct;49(10):633–659.
   PubMed Web of Science ®Google Scholar
• Gill KL, Machavaram KK, Rose RH, et al. Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics. Clin Pharmacokinet. 2016 [2016 Jul 01];55(7):789–805.
   PubMed Web of Science ®Google Scholar
• Ternant D, Bejan-Angoulvant T, Passot C, et al. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin Pharmacokinet. 2015 Nov;54(11):1107–1123.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576–588.
   PubMedGoogle Scholar
• Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548–561.
   PubMed Web of Science ®Google Scholar
• Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008;326(2):555–562.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. [2008 Nov 15];112(10):3959–3964.
   PubMed Web of Science ®Google Scholar
• Lu ZY, Brochier J, Wijdenes J, et al. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol. 1992 Nov;22(11):2819–2824.
   PubMed Web of Science ®Google Scholar
• Montero-Julian FA, Klein B, Gautherot E, et al. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood. [1995 Feb 15];85(4):917–924.
   PubMed Web of Science ®Google Scholar
• FDA. SYLVANT (siltuximab) for injection, for intravenous use 2019 [cited 2022 14 August]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125496s018lbl.pdf
   Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011 Aug;72(2):270–281.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014 Jan;73(1):69–74.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653–1661.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615.
   PubMed Web of Science ®Google Scholar